C07D 211/66
Having a hetero atom as the second substituent in position 4
Official title: having a hetero atom as the second substituent in position 4
C07D211/66 (Having a hetero atom as the second substituent in position 4) appears on 180 US grants and 157 published applications in this corpus.
Search patents in C07D- Granted patents
- 180
- Published applications
- 157
- Assignees
- 110
- Inventors
- 566
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 2 | 0 |
| 1977 | 3 | 0 |
| 1978 | 3 | 0 |
| 1979 | 5 | 0 |
| 1980 | 8 | 0 |
| 1981 | 2 | 0 |
| 1982 | 1 | 0 |
| 1983 | 1 | 0 |
| 1984 | 1 | 0 |
| 1985 | 0 | 0 |
| 1986 | 2 | 0 |
| 1987 | 0 | 0 |
| 1988 | 2 | 0 |
| 1989 | 2 | 0 |
| 1990 | 0 | 0 |
| 1991 | 3 | 0 |
| 1992 | 2 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 5 | 0 |
| 1997 | 5 | 0 |
| 1998 | 2 | 0 |
| 1999 | 2 | 0 |
| 2000 | 5 | 0 |
| 2001 | 10 | 4 |
| 2002 | 13 | 12 |
| 2003 | 4 | 11 |
| 2004 | 12 | 17 |
| 2005 | 6 | 13 |
| 2006 | 7 | 11 |
| 2007 | 5 | 4 |
| 2008 | 3 | 7 |
| 2009 | 3 | 3 |
| 2010 | 2 | 6 |
| 2011 | 8 | 4 |
| 2012 | 3 | 6 |
| 2013 | 4 | 4 |
| 2014 | 3 | 4 |
| 2015 | 3 | 5 |
| 2016 | 4 | 4 |
| 2017 | 4 | 6 |
| 2018 | 7 | 7 |
| 2019 | 4 | 2 |
| 2020 | 2 | 6 |
| 2021 | 1 | 1 |
| 2022 | 4 | 4 |
| 2023 | 2 | 8 |
| 2024 | 1 | 3 |
| 2025 | 3 | 3 |
| 2026 | 4 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Modulators of programmed death-ligand-122 Sep 2026US 12,741,965 B2Southern Research Institute
- Carboxylic acid containing indanyl compounds for the treatment of neurodegenerative diseases12 May 2026US 12,624,003 B2Celgene Corporation
- Glutamine analogs17 Mar 2026US 12,577,201 B2Jacobio Pharmaceuticals Co., Ltd.
- Prostaglandin E2 (PGE2) EP4 receptor antagonists20 Jan 2026US 12,527,779 B2Domain Therapeutics
- Compounds and compositions for treating conditions associated with LPA receptor activity30 Sep 2025US 12,428,375 B2Lhotse Bio, Inc.
- Compounds and compositions for treating conditions associated with lpa receptor activity18 Jun 2026US 2026/0167607 A1Lhotse Bio, Inc.
- Opioid haptens, conjugates, vaccines, and methods of generating antibodies19 Feb 2026US 2026/0049057 A1The Scripps Research Institute
- Compounds and methods for treating cancer18 Sep 2025US 2025/0289794 A1Mayo Foundation for Medical Education and Research
- Polyamide compounds, method for preparing same, and medical use thereof17 Jul 2025US 2025/0230129 A1Jiangsu Nhwa Pharmaceutical Co., Ltd
- Processes and compounds for preparing spiroligomers8 May 2025US 2025/0145644 A1Temple University of the Commonwealth System of Higher Education
Most cited
By later US patents
- Arylsulfonamido-substituted hydroxamic acids110US 5,455,258 ACiba-Geigy Corporation · 1995
- Arylsulfonamido-substituted hydroxamic acids85US 5,552,419 ACiba-Geigy Corporation · 1996
- Arylsufonamido-substituted hydroxamic acids78US 5,506,242 ACiba-Geigy Corporation · 1996
- Aryloxyarylsulfonylamino hydroxamic acid derivatives70US 6,214,872 B1Pfizer Inc. · 2001
- 3-aryl-tetronic acid derivatives, the production thereof and the use thereof as antiparasitic agents55US 5,830,825 ABayer Aktiengesellschaft · 1998